Advertisement
Australia markets close in 1 hour 15 minutes

  • ALL ORDS

    7,948.90
    +11.00 (+0.14%)
     

  • ASX 200

    7,693.10
    +9.60 (+0.12%)
     

  • AUD/USD

    0.6519
    +0.0030 (+0.46%)
     

  • OIL

    83.44
    +0.08 (+0.10%)
     

  • GOLD

    2,340.50
    -1.60 (-0.07%)
     

  • Bitcoin AUD

    102,802.27
    +1,129.69 (+1.11%)
     

  • CMC Crypto 200

    1,436.86
    +22.10 (+1.56%)
     

  • AUD/EUR

    0.6086
    +0.0030 (+0.50%)
     

  • AUD/NZD

    1.0961
    +0.0031 (+0.28%)
     

  • NZX 50

    11,899.32
    +96.04 (+0.81%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    17,110.21
    +281.28 (+1.67%)
     

  • NIKKEI 225

    38,389.13
    +836.97 (+2.23%)
     

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

Replimune Group Inc
Updated ·1-min read

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com